BRIEF-Pepgen Announces Clinical Hold In The U.S. On Ind Application To Initiate Connect2-Edo51 Phase 2 Study

Reuters
16 Dec 2024
BRIEF-Pepgen Announces Clinical Hold In The U.S. On Ind Application To Initiate Connect2-Edo51 Phase 2 Study

Dec 16 (Reuters) - PepGen Inc PEPG.O:

  • PEPGEN ANNOUNCES CLINICAL HOLD IN THE U.S. ON IND APPLICATION TO INITIATE CONNECT2-EDO51 PHASE 2 STUDY OF PGN-EDO51 FOR DUCHENNE MUSCULAR DYSTROPHY

  • CONTINUES TO ADVANCE PGN-EDO51 IN CONNECT1-EDO51, WITH 10 MG/KG COHORT NOW FULLY ENROLLED

Source text: ID:nBw6HxDTNa

Further company coverage: PEPG.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10